Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Replimune secures accelerated approval for oncolytic viral therapy Tudriqev

7 August 2026 · By · Wire by Fusion42

Published

7 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 7 August 2026 · Fusion42 review

The US FDA granted accelerated approval to Replimune's oncolytic viral therapy Tudriqev for adult patients with advanced melanoma resistant to PD-1 blocking antibody treatments, marking the first approval for this specific patient group and combination with nivolumab.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 6 Aug 2026 and 7 Aug 2026.

◆ ◆ The Wire takeaway

You now face a clear regulatory route for viral therapies targeting checkpoint inhibitor-resistant melanoma, making combination immunotherapies a more viable product strategy this year.

◆ Coverage

4 sources · first reported 6 Aug 2026 · latest 7 Aug 2026

◆ Related on Wire

◆ Topics

Biotechoncolytic-virusmelanomafda-approvalimmunotherapyclinical-trials